Abstract: Objective To investigate the clinical efficacy of Shakuba Valsartan in the treatment of chronic heart failure. Methods A total of 60 patients who met the inclusion criteria from July 2018 to December 2019 were randomly divided into observation group and control group with 30 patients in each group. The observation group was treated with Shakuba Valsartan on the basis of conventional treatment, and the control group only received conventional treatment for 6 months. After the end of treatment, the differences in cardiac function, brain natriuretic peptide, blood pressure, renal function, efficacy, and other aspects between the two groups were observed. Results After the end of the course of treatment, the clinical efficacy of the patients in the observation group was significantly better than that in the control group [93.33% (28/30) vs. 73.33% (22/30)] (P<0.05), the descend range of NT-proBNP and systolic blood pressure were better than those in the control group (both P<0.05), the protection of renal function was also better than that in the control group (P<0.05). Conclusion Shakuba Valsartan has remarkable treatment effect in patients with chronic heart failure, with more secure treatment process and less adverse reactions, which is an ideal therapeutic schedule for chronic heart failure patients.

Key words: Shakuba Valsartan, Chronic heart failure, Clinical observation

摘要： 目的 研究沙库巴曲缬沙坦钠片治疗慢性心力衰竭的临床疗效。方法 选取从2018年7月至2019年12月期间符合入组标准的60例患者随机分为观察组和对照组,每组各30例。观察组在常规治疗基础上联合沙库巴曲缬沙坦片治疗;对照组仅采用常规治疗,治疗时间为6个月。待治疗结束后,观察两组患者在心功能、脑钠肽、血压、肾功能、疗效等方面的差异。结果 疗程结束后观察组患者中的临床疗效与对照组比较具有显著提升[93.33%(28/30)比73.33%(22/30)](P<0.05),脑钠肽NT-proBNP下降幅度、收缩压优于对照组(均P<0.05),对肾功能的保护也优于对照组(P<0.05)。结论 沙库巴曲缬沙坦治疗慢性心力衰竭,治疗效果显著,治疗过程更加安全,不良反应少,是慢性心力衰竭较为理想的治疗方案。

关键词: 沙库巴曲缬沙坦钠片, 慢性心力衰竭, 临床观察